All Episodes
NeurologyLive® Mind Moments® — 192 episodes
171: Fragile X Syndrome Day: Clinical Challenges, Care Strategies, and Emerging Therapies
170: Evaluating New MS Diagnostic Criteria in Atypical Presentations
169: A Clinical Guide to Diagnosing and Managing ADEM
168: Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine
167: New AASM Guidance on Combination Treatment for Chronic Insomnia
166: Understanding RNFL Asymmetry as a Biomarker in Pediatric MS
165: Addressing Cognitive Decline in Parkinson Disease
164: Tremor vs Dyskinesia: Practical Bedside Clues for Clinicians
163: The Clinical Reality of Seronegative Myasthenia Gravis
Key Challenges Facing Neurology in the Year Ahead
162: Breaking Down INFUSE Trial Data and Real-World Eptinezumab Use
161: Clinical Takeaways From 2026 International Stroke Conference
160: Early Pathology, Biomarkers, and the Next Phase of DMD Care
Special Episode: The 2026 AHA/ASA Guideline for Early Management of Acute Ischemic Stroke
159: Key Practice Takeaways From the New AAN Functional Seizure Guidelines
158: Bexicaserin, the PACIFIC Trial, and Treating Developmental Epileptic Encephalopathies
157: Clinical Advances and Unanswered Questions in Narcolepsy
156: Building Better Mood and Behavior Care for Parkinson Disease
155: Understanding Variability in Infantile Spasms Care
154: NEALS 2025: Takeaways That Matter for ALS Care
153: Overviewing the 2025 Alzheimer's Association's Blood-Based Biomarker Guidelines
152: Building Safer, Smarter, and More Personalized Epilepsy Care
151: ECTRIMS 2025 Debrief: Precision MS & What’s Next with Daniel Ontaneda
150: Rethinking Parkinson’s Care: Prevention, Equity, and Access to Treatment
Special Episode: Understanding Fremanezumab's Expanded Indication in Pediatric Migraine
149: Overviewing Consensus Guidelines to Standardize Gene Therapy Care in Duchenne
148: Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care
147: Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management
146: Overviewing Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer Care
Breaking Down the FDA’s Latest Migraine Therapy Approvals with Dr. Stewart Tepper
145: Rewiring Stroke Recovery: What the Glymphatic System Can Teach Us
144: Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead
143: Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease
142: World MS Day: Raising Awareness, Evolving Care, and Empowering Patients
141: Refining TSC Care: Phenotyping, Clustering, and Clinical Impact
140: Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress
139: Sleep and Seizures: Emerging Insights From AAN 2025
138: Training the Next Generation of Neurology Nurse Practitioners
Special Episode: What Apomorphine Infusion Approval Means for Parkinson Disease Care
137: Advancing Neuromuscular Care and Research
Special Episode: FDA Approves Tenecteplase for Acute Ischemic Stroke
136: Raising Epilepsy Awareness for Purple Day
135: Invaluable Role of Social Support in Narcolepsy and Idiopathic Hypersomnia Care
134: Previewing the 2025 ACTRIMS Forum
133: Clinical Guidance on Neurostimulation for Lennox-Gastaut Syndrome
132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
131: Neurology Unwrapped: 2024’s Most Intriguing Conversations
130: The Promise Behind Cell Therapy Approaches in Epilepsy
129: Implications of the 2024 AASM Guidelines for Restless Legs Syndrome
128: Machine Learning Algorithms to Predict Seizure Control in Epilepsy Surgery
127: Adapting Neuromuscular and Electrodiagnostic Medicine Education for Modern Learners
Special Episode: FDA Approves Sodium Oxybate for Pediatric Narcolepsy
126: Therapeutic Potential of ATH434 in Multiple System Atrophy
125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy
123: Previewing Cleveland Clinic's Epilepsy Summit
122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
121: Understanding the Potential Cardiovascular Benefits of Low-Sodium Oxybate
115: Expanding Access to Ublituximab and AntiCD20s for Multiple Sclerosis
120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve
119: Utilizing the Syn-One Test to Diagnose Parkinson Disease
Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
118: Gaining Patient Perspectives on Impact of Narcolepsy
117: 2024 Consortium of Multiple Sclerosis Centers Annual Meeting Highlights
116: Understanding Vorasidenib's Therapeutic Benefit on Neurocognition, Seizure Control in Diffuse Gliomas
114: Phase 3 PHOENIX Study, AMX0035, and Amylyx's Future Drug Development
Special Episode: FDA Approval of Diazepam Buccal Film for Pediatric Seizures
113: Lessons Learned in Alzheimer Drug Development
112: Exploring Dimethyl Fumarate to Treat Friedreich Ataxia
Special Episode: FDA Approval of Givinostat for Duchenne Muscular Dystrophy
111: Reviewing ACTRIMS 2024
110: Differential Diagnosis of Sleep Disorders and Hypersomnias
109: AB126, Exosomes, and Cerebroprotection for Stroke
108: Advancing the Genetic Pool of Parkinson Disease
107: Revealing Mechanisms of Sudden Unexplained Death in Toddlers
106: Potential Role of Stathmin-2 in Amyotrophic Lateral Sclerosis
105: Recapping Conversations in Neurology From 2023
104: Effects of Once-Nightly Sodium Oxybate on Narcolepsy Type 1 and 2
103: Advancing Epilepsy Care and Seizure Localization in Pediatrics
102: Potential of Gamma Sensory Stimulation in Alzheimer Disease
Special Episode: FDA Greenlights Vamorolone for Duchenne Muscular Dystrophy
101: Ways to Enhance Neuromodulation in Parkinsonism
Special Episode: FDA Approves Zilucoplan for Myasthenia Gravis
100: 2023 ECTRIMS-ACTRIMS Meeting Highlights
99: Understanding AMX0035's Potential in Progressive Supranuclear Palsy
98: Uncovering Phenotypical Features of Narcolepsy Type 1
97: Identifying Gaps in Access to Parkinson Disease Care
96: Complexities With Cognitive Screening in Primary Care Settings
Special Episode: Addition of Valbenazine to Treat Huntington Disease Chorea
95: Expanding Potential for Long-Term Treatment in SMA
94: The Discussion Surrounding Lecanemab's Approval for Alzheimer Disease
93: Caring for Women With Parkinson Disease
92: Highlights From the 2023 CMSC, SLEEP, AHS, and ATMRD Annual Meetings
Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy
91: Assessing the Landscape of Sleep Disorder Care
90: Raising Stroke Awareness and Improving Clinical Care
89: Potential of CNM-Au8 Gold Nanocrystals to Treat ALS
88: 2023 AAN Annual Meeting Highlights
Special Episode: Tofersen Approved for SOD1 ALS
87: Severe Multiple Sclerosis and the CASA-MS Study
86: Pimavanserin and Atypical Antipsychotics to Treat Parkinson Disease Psychosis
85: Impact of Narcolepsy on Social Relationship Health in Adolescents
Special Episode: Trofinetide Approved for Rett Syndrome
84: Parkinson Disease Education for Community Providers
83: The ARISE Study and Using DMTs in RIS
82: Managing Seizures After Ischemic Stroke
81: Widening the Therapeutic Window in Parkinson Disease
80: Advancing Treatment for Rare Neuromuscular Disorders
Special Episode: Lecanemab Approved for Alzheimer Disease
79: A New Monoclonal for Alzheimer Disease
78: A Virtual Reality Platform for Parkinson Disease
77: A New Era of Myasthenia Gravis Treatment
76: ECTRIMS 2022 and the Latest in MS Advances
75: Focusing on the Future of Neurology
74: Prescription Digital Therapeutics for Insomnia
73: The Role of Palliative Care in Neurology
72: Updates in Epilepsy Treatment
71: Pediatric Sleep and School Start Times
70: Raising Awareness of Acute Flaccid Myelitis
69: The Widespread Effects of DMT Waste in Multiple Sclerosis
68: Updates in Essential Tremor Care
67: Mental Health and Advocacy in Pediatric Migraine
66: 2022 SLEEP Annual Meeting Highlights
Special Episode: Aducanumab and Anti-Amyloid-ß, One Year Later
65: 2022 CMSC Annual Meeting Highlights
64: Genetics, Advocacy, and Big Data in ALS
63: Moving Migraine Toward Personalized Care
62: Advanced Therapeutics in Parkinson and Movement Disorders
61: 2022 AAN Annual Meeting Highlights
Special Episode: Ganaxolone Approved for CDD, Fenfluramine Approved for LGS
60: Improving Care and Raising Awareness for NMOSD
Special Episode: Heart Health in Narcolepsy
59: AASM's Push to End Daylight Saving Time
58: Addressing Parkinson Disease Virtually With Prime PD
57: Invisible Symptoms: Cognition and MS
56: Epstein-Barr Virus's Relationship With Multiple Sclerosis
55: Treating Headache in the Emergency Department
Special Episode: Daridorexant Approved for Insomnia
54: The Shortage of Neurologists
53: A Landmark Year for Alzheimer Disease
52: Treating Pediatric Migraine
51: The State of Sleep Medicine
50: Genetic Testing for Huntington Disease
49: Altering the View of MS With a Topographical Model
48: RapidAI's Effect on Stroke Imaging
47: Incorporating Physical Therapy Into MS Care
46: Tackling Barriers to Migraine Care
45: Small Victories: Advancing Care in Parkinson Disease
44: AHA/ASA Updates to the Stroke Care Model
43: Is Telehealth Here to Stay for Alzheimer Disease Care?
42: The Importance of Sleep for Overall Health
41: Consensus MRI Guidelines for MS
40: SLEEP 2021: Topline Data, Telemedicine, and Takeaways
39: A Controversial FDA Decision
38: Advancing MS Care and Awareness
37: The Impact of Awareness Efforts in ALS
36: Zavegepant and the Gepant Class for Migraine Care
35: Highlights From the AAN Annual Meeting
34: Hope and the Huntington Disease Pipeline
33: Problem Recognition: Cerebral Palsy Diagnosis
32: The Gaps in Migraine Care for Women
31: The Pipeline Pendulum in Parkinson Disease
30: Cognitive Behaviorial Therapy for Insomnia
29: Developing A Seizure Action Plan
28: The Multiple Sclerosis Patient Journey
27: Short, Sudden, Strange, Similar Spells
26: Digital Approaches to Comprehensive Care in MS
25: 2020 Wrap Up: Silver Linings
24: Aducanumab and Alzheimer Disease Clinical Trials
23: Real-World Acute Migraine Care
22: Capitalizing on Collaboration in Neurology Care
21: How Social Isolation Can Affect Disease Severity
20: Taking Steps to Advance Sleep Care
19: The Vascular Implications of Alzheimer Disease
18: Preventing Tonic-Clonic Seizures in Refractory Epilepsy
17: The Metamorphosis of Migraine: Discovery and Development
16: Personalizing Our Approach to Medication Adherence in Parkinson Disease
15: A New Approval: The SMA Treatment Landscape
14: Trends in the Alzheimer Clinical Pipeline
13: Sequencing SNPs in Huntington Disease
12: Masculinity and Multiple Sclerosis
11: Exploring the Link Between Stroke and COVID-19
10: Neurology and COVID-19: Perspectives From the Front Line
9: Innovation in the Parkinson Disease Pipeline
8: Adapting Neurologic Care During the COVID-19 Pandemic
7: No Relief: Rising MS Drug Prices
6: Time Is Brain: Why EMS Transport Protocols Matter
5: Gut Bacteria and the Brain: An Evolving Role in Epilepsy
4: Only the Beginning: Advancing Migraine Treatment
3: Using Technology to Broaden Stroke Care
2: Alzheimer Disease Update: Is Amyloid Really Dead?
1: State of CBD: Not All Cannabidiol Is Created Equal